文献速递血管炎

用玛瑞利单抗阻断GM-CSF受体α可减少巨细胞动脉炎患者离体培养动脉中的浸润细胞、促炎标志物及新生血管形成

Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis.
PubMed 文献 · Ann Rheum Dis · 2022-01-19

该研究检测巨细胞动脉炎(GCA)动脉病变中GM-CSF及其受体的表达,并分析GM-CSF受体相关信号通路活化及靶基因表达;在GCA患者离体培养的颞动脉中评估玛瑞利单抗阻断GM-CSF受体α的效应。结果显示GCA病变中GM-CSF及受体α的mRNA和蛋白升高,JAK2/STAT5A表达/磷酸化增强,靶基因CD83和Spi1/PU.1表达增加;玛瑞利单抗减少T细胞、B细胞、单核细胞和NK细胞标志物转录本及浸润的CD16和CD3ε细胞,降低HLA-DR、干扰素-γ、IL-6、TNFα、IL-1β及血管损伤相关分子表达,减少CD34+细胞和新生血管形成。作者认为这些体外抑制效应与2期试验中GCA复发减少的临床观察一致,支持其作为GCA治疗选择进行开发。

要点

  • GCA动脉病变中GM-CSF及GM-CSF受体α的mRNA和蛋白升高,JAK2/STAT5A表达/磷酸化增强。
  • 玛瑞利单抗减少离体培养GCA动脉中CD3ε、CD20、CD14、CD16细胞标志物转录本及浸润的CD16和CD3ε细胞。
  • 玛瑞利单抗降低HLA-DR、干扰素-γ、IL-6、TNFα、IL-1β及MMP9、脂质过氧化产物、iNOS表达,减少CD34+细胞和新生血管形成。

核心结论

  • 玛瑞利单抗在体外对GCA发病级联多个步骤的抑制作用与2期试验中GCA复发减少的临床观察一致,支持其作为GCA患者治疗选择进行开发。

研究设计与样本

  • 研究采用定量实时PCR、原位RNA杂交、免疫组化、免疫荧光与共聚焦显微镜、免疫分析、蛋白质印迹及离体颞动脉培养,分析GCA患者动脉病变中GM-CSF及其受体的表达、GM-CSF受体相关信号通路活化及靶基因表达,并评估玛瑞利单抗阻断GM-CSF受体α对离体培养GCA动脉的效应。

主要发现

  • GCA病变中GM-CSF和GM-CSF受体α的mRNA与蛋白升高,JAK2/STAT5A表达/磷酸化增强,靶基因CD83和Spi1/PU.1表达增加。
  • 玛瑞利单抗处理离体培养GCA动脉后,CD3ε、CD20、CD14和CD16细胞标志物转录本减少,免疫荧光显示浸润的CD16和CD3ε细胞减少。
  • 玛瑞利单抗降低T细胞活化相关分子HLA-DR和Th1分化相关分子干扰素-γ的表达,降低促炎细胞因子IL-6、TNFα和IL-1β,以及血管损伤相关分子基质金属蛋白酶9、脂质过氧化产物和诱导型一氧化氮合酶的表达。
  • 玛瑞利单抗减少GCA病变中的CD34+细胞和新生血管形成。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Effective and safe therapies are needed for the treatment of patients with giant cell arteritis (GCA). Emerging as a key cytokine in inflammation, granulocyte-macrophage colony stimulating factor (GM-CSF) may play a role in promoting inflammation in GCA. OBJECTIVES: To investigate expression of GM-CSF and its receptor in arterial lesions from patients with GCA. To analyse activation of GM-CSF receptor-associated signalling pathways and expression of target genes. To evaluate the effects of blocking GM-CSF receptor α with mavrilimumab in ex vivo cultured arteries from patients with GCA. METHODS: Quantitative real time PCR, in situ RNA hybridisation, immunohistochemistry, immunofluorescence and confocal microscopy, immunoassay, western blot and ex vivo temporal artery culture. RESULTS: GM-CSF and GM-CSF receptor α mRNA and protein were increased in GCA lesions; enhanced JAK2/STAT5A expression/phosphorylation as well as increased expression of target genes CD83 and Spi1/PU.1 were observed. Treatment of ex vivo cultured GCA arteries with mavrilimumab resulted in decreased transcripts of CD3ε, CD20, CD14 and CD16 cell markers, and reduction of infiltrating CD16 and CD3ε cells was observed by immunofluorescence. Mavrilimumab reduced expression of molecules relevant to T cell activation (human leukocyte antigen-DR [HLA-DR]) and Th1 differentiation (interferon-γ), the pro-inflammatory cytokines: interleukin 6 (IL-6), tumour necrosis factor α (TNFα) and IL-1β, as well as molecules related to vascular injury (matrix metalloprotease 9, lipid peroxidation products and inducible nitric oxide synthase [iNOS]). Mavrilimumab reduced CD34 + cells and neoangiogenesis in GCA lesions. CONCLUSION: The inhibitory effects of mavrilimumab on multiple steps in the GCA pathogenesis cascade in vitro are consistent with the clinical observation of reduced GCA flares in a phase 2 trial and support its development as a therapeutic option for patients with GCA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Corbera-Bellalta M, Alba-Rovira R, Muralidharan S, et al. Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. Ann Rheum Dis. 2022. PMID: 35045965. doi:10.1136/annrheumdis-2021-220873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。